Effect of urothelial cancer targeting drug Erdafitinib

The efficacy of Erdafitinib was studied in a clinical trial that included 87 patients with locally advanced or metastatic cancers whose FGFR3 or FGFR2 gene alterations had progressed after chemotherapy. The overall response rate for these patients was 32.2%, with 2.3% of patients having a complete response and nearly 30% of patients having a partial response. Responses lasted about five and a half months on average, and patients who had previously failed to respond to anti-PD-L1/PD-1 therapy responded to erdafitinib. Based on clinical trial results, erdafitinib typically begins to show efficacy within weeks of starting treatment. However, this does not mean that every patient will see improvement in the same amount of time.